Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2022; 28(28): 3573-3585
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3573
Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities
Leonardo Gomes da Fonseca, Raphael L C Araujo
Leonardo Gomes da Fonseca, Department of Medical Oncology, Instituto do Cancer do Estado de Sao Paulo, University of Sao Paulo, São Paulo 01246-000, São Paulo, Brazil
Leonardo Gomes da Fonseca, Raphael L C Araujo, Hospital e Maternidade Brasil - Rede D'Or São Luiz, Santo André 09030-590, São Paulo, Brazil
Raphael L C Araujo, Department of Digestive Surgery, Escola Paulista de Medicina - UNIFESP, São Paulo 04023-062, São Paulo, Brazil
Author contributions: Both authors performed the writing and prepared the figures and tables; Both authors designed the outline and coordinated the writing of the paper.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Noncommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Raphael L C Araujo, MD, PhD, Adjunct Professor, Surgical Oncologist, Department of Digestive Surgery, Escola Paulista de Medicina - UNIFESP, Rua Botucatu, 740, Vila Clementino, São Paulo 04023-062, São Paulo, Brazil.
Received: January 17, 2022
Peer-review started: January 17, 2022
First decision: April 11, 2022
Revised: April 19, 2022
Accepted: June 26, 2022
Article in press: June 26, 2022
Published online: July 28, 2022
Core Tip

Core Tip: Management of hepatocellular carcinoma (HCC) is based on stages defined by tumor burden, liver function, and performance status. With the advent of more effective systemic treatments, such as immunotherapy and immunotherapy-based combinations, patients with advanced stage disease have better outcomes. The migration of systemic treatment to earlier stages, in combination with locoregional therapies, are expected to improve the outcomes and cure rates. Currently, the research field is moving towards an increasing interest in combining locoregional and systemic treatments for HCC.